Abstract Search

10.2. Screening for type 1 diabetes in the general population: a status report and perspective

EK Sims , REJ Besser , C Dayan , Rasmussen C Geno , C Greenbaum , KJ Griffin , W Hagopian , M Knip , AE Long , F Martin , C Mathieu , M Rewers , AK Steck , JM Wentworth , SS Rich , O Kordonouri , AG Ziegler , KC Herold

NIDDK Type 1 Diabetes TrialNet Study Group.Diabetes. 2022 Apr 1;71(4):610-623. https://pubmed.ncbi.nlm.nih.gov/35316839/Brief Summary: This is a comprehensive review on general population screening, a current hot topic in the field of type 1 diabetes (T1D). The authors provide a critical overview of the rationale for population screening, arguments for and against it, current efforts to gui...

0 shares

ey0017.10-8 | (1) | ESPEYB17

10.8. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes

KC Herold , BN Bundy , SA Long , JA Bluestone , LA DiMeglio , MJ Dufort , SE Gitelman , PA Gottlieb , JP Krischer , PS Linsley , JB Marks , W Moore , A Moran , H Rodriguez , WE Russell , D Schatz , JS Skyler , E Tsalikian , DK Wherrett , AG Ziegler , CJ Greenbaum , Type 1 Diabetes TrialNet Study Group

To read the full abstract: N Engl J Med. 2019 Aug 15;381(7):603613. doi: 10.1056/NEJMoa 1902226.Type 1 diabetes (T1DM) is a chronic autoimmune disease that leads to destruction of insulin producing beta cells, which leaves the patient dependent on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in T1DM, but interventions to prevent clinic...

1 shares

ey0016.14-4 | (1) | ESPEYB16

14.4. A reprogramming human T cell function and specificity with non-viral genome targeting

TL Roth , C Puig-Saus , R Yu , E Shifrut , J Carnevale , PJ Li , Hiatt , J Saco , P Krystofinski , H Li , V Tobin , DN Nguyen , MR Lee , AL Putnam , AL Ferris , JW Chen , JN Schickel , L Pellerin , D Carmody , G Alkorta-Aranburu , D Del Gaudio , H Matsumoto , M Morell , Y Mao , M Cho , RM Quadros , CB Gurumurthy , B Smith , M Haugwitz , SH Hughes , JS Weissman , K Schumann , JH Esensten , AP May , A Ashworth , GM Kupfer , SAW Greeley , R Bacchetta , E Meffre , MG Roncarolo , N Romberg , KC Herold , A Ribas , MD Leonetti , A Marson

To read the full abstract: Nature. 2018 Jul;559(7714):405409This article decries a CRISPR-Cas9 genome-targeting system that does not require viral vectors, allowing rapid and efficient insertion of large DNA sequences at specific sites in the genomes of primary human T cells, while preserving cell viability and function.The common approach to genetically...

0 shares

ESPE Yearbook of Paediatric Endocrinology

10.2. Screening for type 1 diabetes in the general population: a status report and perspective

10.8. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes

14.4. A reprogramming human T cell function and specificity with non-viral genome targeting

BiosciAbstracts